Brief: Heartbeam Receives FDA Breakthrough Device Designation For Heart Attack Assessment
05/10/2026 13:33
BRIEF-Heartbeam Receives FDA Breakthrough Device Designation For Heart Attack Assessment Oct 5 (Reuters) - HeartBeam, Inc. BEAT.O:
HEARTBEAM RECEIVES FDA BREAKTHROUGH DEVICE DESIGNATION FOR HEART ATTACK ASSESSMENT
Source text: ID:nBw7KvK89a
Further company coverage: BEAT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on HeartBeam
See all newsBrief: Heartbeam Receives FDA Breakthrough Device Designation For Heart Attack Assessment
Brief: HeartBeam Will Not Build Large Commercial Organization For Arrhythmia Indication
Brief: Heartbeam, Inc. Enters Into At-The-Market Equity Offering Sales Agreement For Up To $25 Million In Common Stock
HeartBeam, Inc. reports results for the quarter ended June 30 - Earnings Summary
HeartBeam Q2 loss per share narrows; co lowers FY net operating cash outflow guidance